238 related articles for article (PubMed ID: 36980292)
1. Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective.
Lebedev T; Kousar R; Patrick B; Usama M; Lee MK; Tan M; Li XG
Cells; 2023 Mar; 12(6):. PubMed ID: 36980292
[TBL] [Abstract][Full Text] [Related]
2. ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response.
Bakr A; Corte GD; Veselinov O; Kelekçi S; Chen MM; Lin YY; Sigismondo G; Iacovone M; Cross A; Syed R; Jeong Y; Sollier E; Liu CS; Lutsik P; Krijgsveld J; Weichenhan D; Plass C; Popanda O; Schmezer P
Nucleic Acids Res; 2024 Jun; 52(10):5698-5719. PubMed ID: 38587186
[TBL] [Abstract][Full Text] [Related]
3. ARID1A mutations in cancer development: mechanism and therapy.
Zhang X; Zhang Y; Zhao J; Wu Y; Zhang N; Shen W
Carcinogenesis; 2023 May; 44(3):197-208. PubMed ID: 36882165
[TBL] [Abstract][Full Text] [Related]
4. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
5. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
